Telomerase as Drug and Drug Target for the Treatment of Thyroid Cancer

Author(s): M. A. Zeiger, A. K. Meeker.

Journal Name: Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 4 , Issue 3 , 2004

Submit Manuscript
Submit Proposal

Abstract:

Telomerase is known to be activated in almost all cancer cells and is quiescent in almost all normal cells. Therefore, it follows that therapeutic strategies directed against cancer would include the targeting of telomerase, as well as the use of telomerase. Several approaches have been used both in vitro and in vivo and include the following: 1) antisense; 2) immunotherapy directed against hTERT; and 3) the use of telomerase promoter to direct cytotoxic therapy. Herein we review these approaches and discuss their potential applicability against thyroid cancer.

Keywords: telomerase, thyroid cancer, drug target, immunotherapy, antisense strategy

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 4
ISSUE: 3
Year: 2004
Page: [253 - 256]
Pages: 4
DOI: 10.2174/1568005310404030253
Price: $58

Article Metrics

PDF: 1